Newest Sustained-Release Anti-VEGF Drug in Trials

Posted on January 29, 2021January 29, 2021 by Dan Roberts

January 29, 2021

Newest Sustained-Release Anti-VEGF Drug in Trials

EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend […]

Also posted in

Latest News
Therapies, Treatments, and Procedures

Faricimab for wet AMD effective at 16-week intervals

Posted on January 25, 2021January 26, 2021 by Dan Roberts

January 25, 2021

Faricimab for wet AMD effective at 16-week intervals

Genentech has announced positive topline results from its Phase III studies, TENAYA and LUCERNE, evaluating its new drug faricimab, for people with wet (neovascular) age-related macular degeneration (nAMD). Both studies have shown that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes as effective as those receiving […]

Also posted in

Latest News
Research and Developments

News & Archive Categories

Month: January 2021

Newest Sustained-Release Anti-VEGF Drug in Trials